Payment overview · 2025
General Payments
$212.08
12 reported records · 10 companies
Healthcare provider profile · identity verified
Kevin Koehler, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · TUPELO, MS · NPI 1710955984
Verified facts
What the public records show
CMS Open Payments records show Kevin Koehler, M.D. received $212.08 in general payments during 2025 across 12 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 16.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Wegovy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 126 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 135 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Wegovy as an associated drug or biological on 183056 records involving 75256 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Wegovy by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $33.96 | 16.0% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $32.53 | 15.3% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.50 | 14.4% | 2 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.86 | 9.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $18.85 | 8.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $16.77 | 7.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.59 | 7.8% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.64 | 7.4% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.87 | 6.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.51 | 6.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $212.08 | 12 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $33.96 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $32.53 | 2 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $19.86 | 1 | 2025 |
Source payment records
|
|||||
| TRINTELLIX Normalized: trintellix |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.59 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.64 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.75 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.87 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $13.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 54 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 126 | exact normalized | Medicare Part D |
| Wegovy wegovy |
2025 | Wegovy | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
54 | 24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
126 | 31 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
135 | 24 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Wegovy open payments reported associated product |
CMS Open Payments — General Payments 183056 supporting records · 75256 recipient NPIs · example record 1188130070 |
Wegovy · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
63 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 286 | 81 |
| Amlodipine Besylate | Amlodipine Besylate | 285 | 77 |
| Gabapentin | Gabapentin | 277 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 264 | 73 |
| Levothyroxine Sodium | Levothyroxine Sodium | 157 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 150 | 26 |
| Lisinopril | Lisinopril | 145 | 44 |
| Omeprazole | Omeprazole | 140 | 37 |
| Ozempic | Semaglutide | 135 | 24 |
| Metformin Hcl Er | Metformin Hcl | 128 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 127 | 41 |
| Jardiance | Empagliflozin | 126 | 31 |
| Losartan Potassium | Losartan Potassium | 121 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 116 | 31 |
| Carvedilol | Carvedilol | 107 | 34 |
| Hydrochlorothiazide | Hydrochlorothiazide | 103 | 33 |
| Furosemide | Furosemide | 102 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 85 | 16 |
| Meloxicam | Meloxicam | 84 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 74 | 25 |
| Metformin Hcl | Metformin Hcl | 73 | 20 |
| Montelukast Sodium | Montelukast Sodium | 72 | 21 |
| Valsartan | Valsartan | 71 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 69 | 20 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 68 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 19 |
| Sertraline Hcl | Sertraline Hcl | 66 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 65 | 23 |
| Eliquis | Apixaban | 63 | 12 |
| Famotidine | Famotidine | 62 | 21 |
| Potassium Chloride | Potassium Chloride | 60 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 54 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 54 | 18 |
| Pregabalin | Pregabalin | 51 | suppressed |
| Ibuprofen | Ibuprofen | 48 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 48 | suppressed |
| Spironolactone | Spironolactone | 46 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 43 | 12 |
| Buspirone Hcl | Buspirone Hcl | 42 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 41 | 11 |
| Allopurinol | Allopurinol | 39 | suppressed |
| Clonazepam | Clonazepam | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 37 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 36 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 35 | 14 |
| Simvastatin | Simvastatin | 35 | 11 |
| Mounjaro | Tirzepatide | 33 | suppressed |
| Levetiracetam | Levetiracetam | 29 | suppressed |
| Novolog Flexpen | Insulin Aspart | 29 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 29 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 29 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 27 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 26 | suppressed |
| Levemir Flexpen | Insulin Detemir | 25 | suppressed |
| Mirtazapine | Mirtazapine | 25 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Finasteride | Finasteride | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 21 | suppressed |
| Prednisone | Prednisone | 21 | 15 |
| Trulicity | Dulaglutide | 21 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 21 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 18 | suppressed |
| Celecoxib | Celecoxib | 18 | suppressed |
| Chlorthalidone | Chlorthalidone | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Glimepiride | Glimepiride | 16 | suppressed |
| Glipizide | Glipizide | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 13 |
| Cephalexin | Cephalexin | 15 | 11 |
| Glipizide Er | Glipizide | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Wegovy | Semaglutide | 14 | suppressed |
| Alprazolam | Alprazolam | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Irbesartan | Irbesartan | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Cryselle | Norgestrel-Ethinyl Estradiol | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Novolog Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $212.08 · 12 records | Otsuka America Pharmaceutical, Inc. | ABRYSVO, BREZTRI, CAPLYTA, COMIRNATY, Dexcom G6 Transmitter, FARXIGA, JARDIANCE, PREVNAR 20, Qelbree, REXULTI, TRINTELLIX, VRAYLAR, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error